Abstract 1169P
Background
Acral lentiginous melanoma (ALM), although overall a rare type of melanoma, is the most common form of the disease in a number of countries in Latin America, Africa, and Asia; it is associated with a poor prognosis and recurrence. In this study, we seek to gain a better understanding of the tumor-immune components of ALM and their relationship to transcriptional programs.
Methods
Tumour samples were collected from patients undergoing treatment at the National Cancer Institute of Mexico, and have been annotated with vast clinical information. We performed transcriptome sequencing through exome-capture bulk RNA-sequencing on 65 primary tumors from 64 Mexican patients, and did spatial protein profiling using a tissue microarray on 110 tumor segments from 45 patients. Samples were collected at the National Cancer Institute of Mexico and have been annotated with vast clinical information.
Results
We identified differentially expressed genes such as CXCL8, MMP1, and TERT in ulcerated lesions. RNA deconvolution showed a high abundance of cancer-associated fibroblasts (CAFs) and the absence of NK cells. Consensus clustering identified three ALM subgroups based on global gene expression. Integration of spatial protein information confirmed the high abundance of CAFs- associated markers and the absence of CD56. Fibronectin, SMA, and the cancer stem cell marker CD44 were markedly elevated. We investigated expression patterns within particular regions of interest and found that fibronectin, VISTA, SMA, IDO1, CD34, CD45, CD3, HLA-DR, and CD45RO were differentially expressed in non-tumor regions, while tumor ROIs expressed B7-H3, CD127, GAPDH, and Ki-67 significantly at higher levels. Comparisons between RNA and protein for 35 targets are being conducted.
Conclusions
So far, our analyses point to genes that could drive important prognostic characteristics. We confirmed that ALM is characterized by an immunosuppressive tumor microenvironment. The role of CAFs and the mechanisms affecting NK cells require further research. The present project will enhance our understanding of the TME components and the antitumor response in an understudied disease.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Carla Daniela Robles Espinoza.
Funding
CONACyT A3-S-31603, UNAM PAPIIT IN209422, Welcome Sanger Institute International Fellowship, Melanoma Research Alliance Pilot Award #825924, William Guy Forbeck Research Foundation.
Disclosure
D. Adams: Other, Institutional, Other, DJA is supported by AstraZeneca, OpenTargets and is a paid consultant for Microbiotica: AstraZeneca. All other authors have declared no conflicts of interest.
Resources from the same session
1149P - Prognosis for patients with metastatic Merkel cell carcinoma with a complete response on avelumab treatment
Presenter: Lisanne Zijlker
Session: Poster session 13
1150P - Transforming growth factor-beta-1 and soluble co-inhibitory immune checkpoints as putative drivers of immune suppression in advanced basal cell carcinoma
Presenter: Bernardo Rapoport
Session: Poster session 13
1151P - Characteristics and treatment outcomes in cutaneous adnexal carcinomas
Presenter: Adam Rock
Session: Poster session 13
1152P - Association of immune-related adverse events (irAE) requiring glucocorticoids (GCs) with outcome and biomarkers in advanced cutaneous malignant melanoma (CMM) treated with immune checkpoint inhibitors (ICI)
Presenter: Fernanda Costa Svedman
Session: Poster session 13
1153P - Incidence and characteristics of immunotherapy related adrenal insufficiency in a monocenter, pan-cancer cohort of 4314 patients
Presenter: Minke Lucas
Session: Poster session 13
1154P - Thromboembolic events in patients with melanoma receiving immune checkpoint inhibitors: Incidence and risk factors
Presenter: Daan van Dorst
Session: Poster session 13
1155P - Application of novel machine learning to predict immunotherapy related toxicities for metastatic melanoma patients from baseline 18F-FDG PET/CT scans
Presenter: Roslyn Francis
Session: Poster session 13
1156P - Immune-related adverse events in a nationwide cohort of melanoma patients treated with adjuvant anti-PD1: Seasonal variation and association with outcome
Presenter: Eva Ellebæk
Session: Poster session 13
1157P - Corticosteroids and second-line immunosuppressants for immune-related adverse events and melanoma survival
Presenter: Rik Verheijden
Session: Poster session 13
1158P - Association of corticosteroid (CS) exposure with treatment failure in patients (pts) with advanced melanoma treated with immune checkpoint inhibitors (ICIs)
Presenter: Ha Mo Linh Le
Session: Poster session 13